Cite
HARVARD Citation
George, D. et al. (n.d.). Number needed to harm (NNH) in patients with non-metastatic, castration-resistant prostate cancer (nmCRPC): A final analysis from the darolutamide (D), enzalutamide (E), and apalutamide (A) clinical trials.. Journal of clinical oncology. 40 (28), p. 326. [Online].